variation differentially regulates influencing HIV disease outcome.

Multiple genome-wide studies have identified associations between outcome of HIV infection and polymorphisms in/around the gene encoding the HIV co-receptor CCR5, but the functional basis for the strongest of these associations, rs1015164 A/G, is unknown. We found that rs1015164, located 34KB downstream of CCR5, marks variation in an ATF1 binding site that controls expression of the antisense long non-coding RNA CCR5AS. Knockdown or enhancement of CCR5AS expression resulted in a corresponding change in CCR5 expression on CD4 + T cells. CCR5AS interfered with interactions between the RNA-binding protein Raly and the CCR5 3’ untranslated region, protecting CCR5 mRNA from Raly-mediated degradation. Reduction in CCR5 expression through inhibition of CCR5AS diminished infection of CD4 + T cells with CCR5-tropic HIV in vitro. These data represent a rare determination of the functional importance of a genome-wide disease association where expression of a long non-coding RNA affects level of HIV infection and disease progression. in site; unlikely to be directly responsible for differential However, a variant located in the first intron of CCR5AS, rs2027820, may directly affect expression levels of this gene, as it is located within a binding site for the transcription factor ATF1 and it is in virtually perfect LD with rs1015164. ATF1 belongs to the cAMP-regulated enhancer-binding (CREB) family of transcription factors and is expressed in a wide variety of cell types 41 . We show that rs2027820G, which is in LD with rs1015164A, allows binding of ATF1 and enhances protein expression in a luciferase assay relative to rs2027820A, indicating that the rs2027820G variant enhances CCR5AS expression levels, whereas the A variant confers poor binding of ATF1 and relatively poor expression of CCR5AS. reporter psicheck2 vector. Hut-78 cells were transfected with either the non-targeting siCon or siRaly. Seventy-two hours after siRNA transfection, the CCR5 3’UTR luciferase constructs were transfected into siCon or siRaly transfected Hut-78 cells. Twenty four hours after transfection of the luciferase constructs, the cells were lysed and luciferase activity was measured. Renilla and firefly luciferase activity were estimated by dual luciferase assays and presented as the normalized ratio of Renilla vs Firefly luciferase activity. The data represent six replicates in each group from two independent experiments. The mean ±SE are depicted as horizontal and vertical bars for each group, respectively. Non-parametric Wilcoxon-Mann-Whitney tests were used for statistical comparisons and two tailed p value is indicated.

[1]  Guohui Li,et al.  Long Non-coding RNAs: Regulators of Viral Infection and the Interferon Antiviral Response , 2018, Front. Microbiol..

[2]  Kotb Abdelmohsen,et al.  Cytoplasmic functions of long noncoding RNAs , 2018, Wiley interdisciplinary reviews. RNA.

[3]  J. Mendell,et al.  Functional Classification and Experimental Dissection of Long Noncoding RNAs , 2018, Cell.

[4]  Xuetao Cao,et al.  An interferon-independent lncRNA promotes viral replication by modulating cellular metabolism , 2017, Science.

[5]  J. Gu,et al.  Energy stress-induced lncRNA FILNC1 represses c-Myc-mediated energy metabolism and inhibits renal tumor development , 2017, Nature Communications.

[6]  Howard Y. Chang,et al.  Gene regulation in the immune system by long noncoding RNAs , 2017, Nature Immunology.

[7]  M. Carrington,et al.  Host genetic variation and HIV disease: from mapping to mechanism , 2017, Immunogenetics.

[8]  H. Garg,et al.  CCR5 promoter activity correlates with HIV disease progression by regulating CCR5 cell surface expression and CD4 T cell apoptosis , 2017, Scientific Reports.

[9]  Jordan A. Ramilowski,et al.  An atlas of human long non-coding RNAs with accurate 5′ ends , 2017, Nature.

[10]  Anne W. Ndungu,et al.  Polymorphism in a lincRNA Associates with a Doubled Risk of Pneumococcal Bacteremia in Kenyan Children , 2016, American journal of human genetics.

[11]  Farooq Rashid,et al.  Long Non-coding RNAs in the Cytoplasm , 2016, Genom. Proteom. Bioinform..

[12]  G. Bhagat,et al.  A long noncoding RNA associated with susceptibility to celiac disease , 2016, Science.

[13]  D. Goldstein,et al.  Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load , 2015, Proceedings of the National Academy of Sciences.

[14]  Mardge H. Cohen,et al.  CCR5 Expression Levels in HIV-Uninfected Women Receiving Hormonal Contraception. , 2015, The Journal of infectious diseases.

[15]  Mary Carrington,et al.  The impact of host genetic variation on infection with HIV-1 , 2015, Nature Immunology.

[16]  J. Foekens,et al.  CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer , 2013, Genome research.

[17]  Howard Y. Chang,et al.  Control of somatic tissue differentiation by the long non-coding RNA TINCR , 2012, Nature.

[18]  Jingyuan Fu,et al.  Human Disease-Associated Genetic Variation Impacts Large Intergenic Non-Coding RNA Expression , 2013, PLoS genetics.

[19]  Manel Esteller,et al.  Cis-acting noncoding RNAs: friends and foes , 2012, Nature Structural &Molecular Biology.

[20]  Shane J. Neph,et al.  Systematic Localization of Common Disease-Associated Variation in Regulatory DNA , 2012, Science.

[21]  Kotb Abdelmohsen,et al.  LincRNA-p21 suppresses target mRNA translation. , 2012, Molecular cell.

[22]  C. Tiemessen,et al.  Marked differences in CCR5 expression and activation levels in two South African populations , 2012, Immunology.

[23]  ENCODEConsortium,et al.  An Integrated Encyclopedia of DNA Elements in the Human Genome , 2012, Nature.

[24]  Joseph K. Pickrell,et al.  DNaseI sensitivity QTLs are a major determinant of human expression variation , 2011, Nature.

[25]  Nicholas T. Ingolia,et al.  Ribosome Profiling of Mouse Embryonic Stem Cells Reveals the Complexity and Dynamics of Mammalian Proteomes , 2011, Cell.

[26]  Manolis Kellis,et al.  PhyloCSF: a comparative genomics method to distinguish protein coding and non-coding regions , 2011, Bioinform..

[27]  Silke Szymczak,et al.  Genetics and Beyond – The Transcriptome of Human Monocytes and Disease Susceptibility , 2010, PloS one.

[28]  A. Heredia,et al.  CCR5 density levels on primary CD4 T cells impact the replication and Enfuvirtide susceptibility of R5 HIV-1 , 2007, AIDS.

[29]  J. Goedert,et al.  Genetic Protection against Hepatitis B Virus Conferred by CCR5Δ32: Evidence that CCR5 Contributes to Viral Persistence , 2006, Journal of Virology.

[30]  D. Dimitrov,et al.  Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration. , 2006, Biochemical and biophysical research communications.

[31]  W. Borkowsky,et al.  CCR5 expression and duration of high risk sexual activity among HIV-seronegative men who have sex with men , 2006, AIDS.

[32]  D. McDermott,et al.  CCR5 deficiency increases risk of symptomatic West Nile virus infection , 2006, The Journal of experimental medicine.

[33]  M. Parmentier,et al.  CCR5 deficiency exacerbates T‐cell–mediated hepatitis in mice , 2005, Hepatology.

[34]  J. Clot,et al.  Relationship between CCR5 density and viral load after discontinuation of antiretroviral therapy. , 2004, JAMA.

[35]  M. Lederman,et al.  R5 HIV productively infects Langerhans cells, and infection levels are regulated by compound CCR5 polymorphisms , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[36]  A. Gervaix,et al.  Response to treatment and disease progression linked to CD4+ T cell surface CC chemokine receptor 5 density in human immunodeficiency virus type 1 vertical infection. , 2002, The Journal of infectious diseases.

[37]  F. Chisari,et al.  Natural Killer T Cell Activation Inhibits Hepatitis B Virus Replication in Vivo , 2000, The Journal of experimental medicine.

[38]  A. J. Valente,et al.  Evolution of Human and Non-human Primate CC Chemokine Receptor 5 Gene and mRNA , 2000, The Journal of Biological Chemistry.

[39]  M J Dolan,et al.  Race-specific HIV-1 disease-modifying effects associated with CCR5 haplotypes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[40]  D. Weissman,et al.  Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[41]  J. Farber,et al.  Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. , 1999, Annual review of immunology.

[42]  J. Goedert,et al.  Genetic acceleration of AIDS progression by a promoter variant of CCR5. , 1998, Science.

[43]  P. O’Connell,et al.  Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression , 1998, Nature Medicine.

[44]  C. Mackay,et al.  Reduced HIV-1 infectability of CD4+ lymphocytes from exposed-uninfected individuals: association with low expression of CCR5 and high production of beta-chemokines. , 1998, Virology.

[45]  J J Goedert,et al.  Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. , 1997, Science.

[46]  Nancy Sullivan,et al.  CCR5 Levels and Expression Pattern Correlate with Infectability by Macrophage-tropic HIV-1, In Vitro , 1997, The Journal of experimental medicine.

[47]  J J Goedert,et al.  Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene , 1996, Science.

[48]  Diana Barkan,et al.  Friends and foes , 1992, Nature.

[49]  R. Goodman,et al.  The cAMP-regulated enhancer-binding protein ATF-1 activates transcription in response to cAMP-dependent protein kinase A. , 1991, The Journal of biological chemistry.